Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis

被引：16

作者：

Barnett, AI

Crémieux, PY

机构：

[1] Anal Grp, Boston, MA 02199 USA

[2] MIT, Sloan Sch Management, Cambridge, MA 02139 USA

来源：

PHARMACOTHERAPY | 2003年 / 23卷 / 05期

关键词：

D O I：

10.1592/phco.23.5.690.32195

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：690 / 693

页数：4

共 9 条

[1]

*AN GROUP, 2003, DAT FIL

[2]

*CTR BIOL EV RES, 2001, MED OFF CLIN REV BLA, P68

[3]

*CTR MED MED SERV, 2003, PAYM EP PROC AR UND

[4]

GRAF H, 2000, J AM SOC NEPHROL, V11, pA1317

[5]

LACOMBE JL, IN PRESS CLIN NEPHRO

[6]

Nissenson AR, 2000, J AM SOC NEPHROL, V11, P591

[7] Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients [J].

Nissenson, AR ;

Swan, SK ;

Lindberg, JS ;

Soroka, SD ;

Beatey, R ;

Wang, C ;

Picarello, N ;

McDermott-Vitak, A ;

Maroni, BJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (01) :110-118

[8] Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies [J].

Scott, SD .

PHARMACOTHERAPY, 2002, 22 (09) :160S-165S

[9]

VANRENTERGHEM Y, 1999, J AM SOC NEPHROL, V10, pA1365

← 1 →